Petra Rietschel, MD: Breast Cancer Treatment May Prove

Petra Rietschel, MD: Breast Cancer Treatment May Prove Beneficial in
Melanoma Cases 
Abraxane, Currently Approved for Breast Cancer Treatment, Has Shown
Promise as a Therapy Option for Metastatic Melanoma; Petra Rietschel,
MD Asserts That Such a Shift in Use of the Drug Is Welcome If
WHITE PLAINS, NY -- (Marketwire) -- 10/29/12 --  Cancer treatments
have evolved a great deal over the last few decades, and many of
today's researchers are focusing on ways in which they can combine
and cross-prescribe these drugs to effectively combat a variety of
conditions. Reuters reports that Celgene Corp has completed a
late-stage clinical trial testing the efficacy of its breast cancer
treatment Abraxane when used to fight metastatic melanoma. The
results of the trial are promising, and Petra Rietschel, MD and other
healthcare professionals are looking forward to future information
regarding the potential use of this treatment method within the
general population.  
According to the article, "Celgene is hoping to win approval to
market it [Abraxane] for other types of cancer, including pancreatic
cancer and melanoma, which, left untreated, is the deadliest form of
skin cancer." Thus far, the only details released are that the
patients who have metastatic melanoma and took Abraxane survived
longer without having their condition worsen than those who underwent
dacarbazine, which is the standard chemotherapy treatment for the
condition; however, Celgene Corp. has not released further details
regarding the specific success of its most recent trial. With an
estimated 132,000 individuals receiving a diagnosis of melanoma each
year, it is certain that improved treatment options would benefit the
patients who are fighting this disease.  
There are, however, other drugs currently on the market with which
Abraxane would compete. The article notes that Yervoy and Zelboraf
are two treatment options that are already on the market. Dr.
Rietschel understands that patients may have differing reactions to
certain medications. As such, she believes that another drug would
only benefit individuals facing cancer, as it would allow them access
to more options should they be unable to take any of the drugs
currently offered.  
"The approval of Yervoy and Zelboraf for metastatic melanoma h
shifted the attention away from chemotherapy regarding this
particular disease," asserts Petra Rietschel, MD. "The only
FDA-approved chemotherapy for metastatic melanoma is DTIC, which was
never compared to any other chemotherapy or even supportive care.
With a response rate around 15 percent and many toxicities, there is
a lot of room for improvement and the approval of a better tolerated
drug with a higher degree of efficacy would certainly be welcomed if
the data from Celgene can show what the company is promising."  
Dr. Rietschel looks forward to learning more about Abraxane as its
role as a melanoma treatment option continues to be investigated.  
Petra Rietschel, MD has an MD and a PhD from the University of
Heidelberg in Germany. Currently, Petra Rietschel, MD participates in
multiple programs that span several medical centers, including
Montefiore Medical Center, Albert Einstein College of Medicine, and
Montefiore Einstein Cancer Center. Petra Rietschel, MD specializes in
melanoma, breast cancer, and sarcoma. 
PR Management Inc.
Contact: George Montgomery 
Phone: 484-362-9658
Press spacebar to pause and continue. Press esc to stop.